GIP agonists have been found to alleviate symptoms that are a result of neurodegenerative diseases that exhibit significant insulin resistance, like AD, by reducing the amount of neuronal plaque caused by neuroinflammation [52]. The gene discussed is GIP; the disease is Alzheimer disease.